Invariant natural killer T (iNKT) cells represent a unique lymphocyte subset that bridges innate and adaptive immunity. Their development originates in the thymus from double‐positive precursor cells, ...
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) ...
A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, shows promising results in ...
Study data show stronger Ph+ acute lymphoblastic leukaemia immune activation with dasatinib plus blinatumomab than with ponatinib combinations, highlighting sustained natural killer cell responses.
The complete remission of a testicular cancer patient receiving Mink Therapeutics Inc.’s allogeneic, off-the-shelf invariant natural killer T-cell therapy Agent-797 with nivolumab drove the company’s ...
Vigencell Inc. plans to seek conditional approval in South Korea for VT-EBV-N, an antigen-specific killer T-cell therapy for natural killer T-cell lymphoma, after gaining positive top-line data from a ...
Detailed price information for Cytomed Therapeutics Limited (GDTC-Q) from The Globe and Mail including charting and trades.
Hosted on MSN
Scientists discover 'natural cancer killer' is 'safer and more effective' than standard treatment
Top experts have developed new 'natural killer' cells to fight off cancer and lower the risk of disastrous immune effects. Researchers at Harvard Medical School and the Massachusetts Institute of ...
Bottom Line: Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body’s natural response to viral infections, showed promising results in patients with relapsed or refractory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results